FR3063906B1 - Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate - Google Patents

Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Info

Publication number
FR3063906B1
FR3063906B1 FR1752284A FR1752284A FR3063906B1 FR 3063906 B1 FR3063906 B1 FR 3063906B1 FR 1752284 A FR1752284 A FR 1752284A FR 1752284 A FR1752284 A FR 1752284A FR 3063906 B1 FR3063906 B1 FR 3063906B1
Authority
FR
France
Prior art keywords
prostate diseases
copaifera oleoresin
copaifera
oleoresin
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1752284A
Other languages
English (en)
French (fr)
Other versions
FR3063906A1 (fr
Inventor
Christel Fiorini-Puybaret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Laboratorios Pierre Fabre Do Brasil Ltda
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1752284A priority Critical patent/FR3063906B1/fr
Application filed by Laboratorios Pierre Fabre Do Brasil Ltda, Pierre Fabre Medicament SA filed Critical Laboratorios Pierre Fabre Do Brasil Ltda
Priority to MX2019011118A priority patent/MX2019011118A/es
Priority to CA3056293A priority patent/CA3056293A1/fr
Priority to JP2019551555A priority patent/JP7305546B2/ja
Priority to EP18711130.7A priority patent/EP3600370B1/fr
Priority to BR112019018744-8A priority patent/BR112019018744B1/pt
Priority to ES18711130T priority patent/ES2979106T3/es
Priority to RU2019132832A priority patent/RU2773173C2/ru
Priority to PCT/EP2018/057076 priority patent/WO2018172380A1/fr
Priority to AU2018240405A priority patent/AU2018240405B2/en
Priority to US16/495,771 priority patent/US11311591B2/en
Priority to KR1020197028071A priority patent/KR102686593B1/ko
Priority to MA48970A priority patent/MA48970B1/fr
Priority to CN201880018902.4A priority patent/CN110494149A/zh
Priority to PL18711130.7T priority patent/PL3600370T3/pl
Publication of FR3063906A1 publication Critical patent/FR3063906A1/fr
Application granted granted Critical
Publication of FR3063906B1 publication Critical patent/FR3063906B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1752284A 2017-03-20 2017-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate Active FR3063906B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR1752284A FR3063906B1 (fr) 2017-03-20 2017-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
US16/495,771 US11311591B2 (en) 2017-03-20 2018-03-20 Use of copaifera oleoresin in pathologies of the prostate
JP2019551555A JP7305546B2 (ja) 2017-03-20 2018-03-20 前立腺の病変におけるＣｏｐａｉｆｅｒａ属オレオレジンの使用
EP18711130.7A EP3600370B1 (fr) 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
BR112019018744-8A BR112019018744B1 (pt) 2017-03-20 2018-03-20 Uso de oleorresina de copaifera em patologias da próstata e composição farmacêutica
ES18711130T ES2979106T3 (es) 2017-03-20 2018-03-20 Uso de oleorresina de copaifera en patologías de la próstata
RU2019132832A RU2773173C2 (ru) 2017-03-20 2018-03-20 Применение олеорезинов копаиферы при патологиях простаты
PCT/EP2018/057076 WO2018172380A1 (fr) 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
MX2019011118A MX2019011118A (es) 2017-03-20 2018-03-20 Uso de oleorresina de copaifera en patologias de la prostata.
CA3056293A CA3056293A1 (fr) 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
KR1020197028071A KR102686593B1 (ko) 2017-03-20 2018-03-20 전립선 병리상태에서 코파이페라 올레오레진의 용도
MA48970A MA48970B1 (fr) 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
CN201880018902.4A CN110494149A (zh) 2017-03-20 2018-03-20 香脂树属油树脂在前列腺病变中的用途
PL18711130.7T PL3600370T3 (pl) 2017-03-20 2018-03-20 Zastosowanie oleożywicy z Copaifera w chorobach gruczołu krokowego
AU2018240405A AU2018240405B2 (en) 2017-03-20 2018-03-20 Use of Copaifera oleoresin in pathologies of the prostate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1752284 2017-03-20
FR1752284A FR3063906B1 (fr) 2017-03-20 2017-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Publications (2)

Publication Number Publication Date
FR3063906A1 FR3063906A1 (fr) 2018-09-21
FR3063906B1 true FR3063906B1 (fr) 2025-12-12

Family

ID=59153043

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1752284A Active FR3063906B1 (fr) 2017-03-20 2017-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Country Status (14)

Country Link
US (1) US11311591B2 (https=)
EP (1) EP3600370B1 (https=)
JP (1) JP7305546B2 (https=)
KR (1) KR102686593B1 (https=)
CN (1) CN110494149A (https=)
AU (1) AU2018240405B2 (https=)
BR (1) BR112019018744B1 (https=)
CA (1) CA3056293A1 (https=)
ES (1) ES2979106T3 (https=)
FR (1) FR3063906B1 (https=)
MA (1) MA48970B1 (https=)
MX (1) MX2019011118A (https=)
PL (1) PL3600370T3 (https=)
WO (1) WO2018172380A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020089944A1 (en) * 2018-11-03 2020-05-07 Olene Life Sciences Private Limited Process for preparing an herbal extract and compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH698144B1 (fr) * 2003-09-24 2009-05-29 Bioxell Spa Analogue de la vitamine D3

Also Published As

Publication number Publication date
RU2019132832A3 (https=) 2021-06-11
MA48970A (fr) 2021-03-31
EP3600370B1 (fr) 2024-04-03
BR112019018744A2 (pt) 2020-04-07
JP2020511488A (ja) 2020-04-16
PL3600370T3 (pl) 2024-07-29
BR112019018744B1 (pt) 2023-02-23
KR102686593B1 (ko) 2024-07-18
KR20190126091A (ko) 2019-11-08
AU2018240405A1 (en) 2019-11-07
CA3056293A1 (fr) 2018-09-27
RU2019132832A (ru) 2021-04-21
EP3600370C0 (fr) 2024-04-03
EP3600370A1 (fr) 2020-02-05
FR3063906A1 (fr) 2018-09-21
ES2979106T3 (es) 2024-09-24
AU2018240405B2 (en) 2024-04-11
US20200093879A1 (en) 2020-03-26
WO2018172380A1 (fr) 2018-09-27
MA48970B1 (fr) 2024-06-28
US11311591B2 (en) 2022-04-26
CN110494149A (zh) 2019-11-22
MX2019011118A (es) 2019-11-05
JP7305546B2 (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
EA202090655A1 (ru) Комбинированные терапевтические средства и их применение
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
MA39285A (fr) Peptides macrocycliques utiles comme immunomoldulateurs
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX2017013533A (es) Composiciones de limpieza personal concentradas.
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
EP4302782A3 (en) Napi2b-targeted antibody-drug conjugates and methods of use thereof
EA201790992A1 (ru) Иммунорегуляторные агенты
EA202092225A1 (ru) Соединения и их применение
MX395085B (es) Tratamiento conjunto contra tipos de cancer hematologico.
MX2019002960A (es) Oligonucleótidos modificados y métodos de uso.
BR112022000855A2 (pt) Moduladores de nlrp3
MX2017013534A (es) Composiciones concentradas para la limipieza personal y usos.
SA521430519B1 (ar) مثبطات مسار تبادل إشارات التحزيز واستخدامها في علاج السرطانات
EP3432872A4 (en) COMPOSITIONS AND METHODS FOR USE OF EFLORNITHIN AND DERIVATIVES AND ANALOGUE THEREOF FOR THE TREATMENT OF CANCER, INCLUDING GLIOMEN
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
EA202192047A1 (ru) Соединения и их применение
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
FR3063906B1 (fr) Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
FR3070004B1 (fr) Utilisation therapeutique ou non-therapeutique de protozoaires du genre willaertia comme fongistatique et/ou fongicide
EA202191469A1 (ru) Восстановление посредством антисмысловых олигонуклеотидов abca4 с аберрантным сплайсингом
EP3876934A4 (en) USE OF TIVOZANIB TO TREAT PEOPLE WITH REFRACTORY CANCER
EP3721891A4 (en) HERBAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BENIGNER PROSTATE HYPERPLASIA

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180921

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: PIERRE FABRE MEDICAMENT, FR

Effective date: 20190808

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10